Amgen (AMGN) Laps the Stock Market: Here's Why

In the latest trading session, Amgen (AMGN) closed at $349.69, marking a +1.43% move from the previous day. This move outpaced the S&P 500's daily gain of 0.5%. On the other hand, the Dow registered a gain of 0.64%, and the technology-centric Nasdaq increased by 0.43%. The world's largest biotech drugmaker's stock has climbed by 3.55% in the past month, exceeding the Medical sector's loss of 0.63% and the S&P 500's gain of 0.18%.Investors will be eagerly watching for the performance of Amgen in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 3, 2026. It is anticipated that the company will report an EPS of $4.74, marking a 10.73% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $9.46 billion, reflecting a 4.16% rise from the equivalent quarter last year. For the full year, the Zacks Consensus Estimates project earnings of $21.27 per share and a revenue of $36.35 billion, demonstrating changes of +7.21% and 0%, respectively, from the preceding year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Amgen. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 0.22% higher. Right now, Amgen possesses a Zacks Rank of #3 (Hold). From a valuation perspective, Amgen is currently exchanging hands at a Forward P/E ratio of 15.86. Its industry sports an average Forward P/E of 20.09, so one might conclude that Amgen is trading at a discount comparatively. We can additionally observe that AMGN currently boasts a PEG ratio of 3.06. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.45 as of yesterday's close. The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 87, putting it in the top 36% of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Zacks.com. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks